Clinical trial NCT05093036: E-Health for Zero Infections - Facilitating Access to and Use of HIV Pre-Exposure Prophylaxis (PrEP) in the Netherlands
Official title: The EZI-PrEP Study: E-Health for Zero Infections - Facilitating Access to and Use of HIV Pre-Exposure Prophylaxis (PrEP) in the Netherlands
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: Pre-Exposure Prophylaxis (PrEP)
Prevention
E-Health
Lead sponsor: Public Health Service of Amsterdam
Sponsor class: OTHER_GOV
Collaborators: name: Public Health Service Rotterdam-Rijnmond
name: Public Health Service Haaglanden
name: Public Health Service Gelderland-Zuid
name: The National Institute for STI and Aids Control in the Netherlands (Soa Aids Nederland)
name: Stichting Aidsfonds
name: DC Pharmacy of DC Klinieken
First posted: 2021-10-26
Enrollment: 469
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: We will implement a multi-center, four-arm, non-inferiority randomised controlled trial to evaluate online PrEP care and/or a reduced schedule of monitoring visits against routine (face-to-face) PrEP care at the Centers of Sexual Health (CSH) of the Public Health Services (PHS) (standard-of-care). After eligibility screening and assessment, study participants are randomized (1:1:1:1) to the standard-of-care arm (i.e. location: CSH; 4 annual monitoring visits) or one of three interventions arms: arm 2 (location: CSH; 2 annual monitoring visit), arm 3 (location: online; 4 annual monitoring visits), arm 4 (location: online; 2 annual monitoring visits). In the randomization process, participants will be stratified based on PrEP experience (PrEP-naïve or experienced) and PHS catchment area (4 regions). In each arm, we aim to include at least 25% PrEP-naïve participants.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Offering PrEP care online and reducing the frequency of monitoring may increase access to HIV PrEP. The objective of this study is to assess the non-inferiority of an internet-based HIV PrEP-service and reduced frequency of monitoring visits in comparison to standard-of-care at the Public Health Service in 4 regions in the Netherlands: Amsterdam, Rotterdam-Rijnmond, Haagland and Gelderland-Zuid.

Detailed description: Rationale: The population impact of HIV pre-exposure prophylaxis (PrEP) largely depends on the uptake and consistent use of PrEP by people at high risk for HIV infection. In the Dutch National PrEP Programme (NPP), PrEP care consists of quarterly monitoring visits, which includes testing for HIV, sexually transmitted infections (STIs) and renal function, and provision of combination tablets of tenofovir disoproxil fumarate and emtricitabine. PrEP care is available for men who have sex with men (MSM) and transgender persons (TGP) at low cost through the centers for sexual health (CSH) of public health services (GGD's). Offering PrEP care online and reducing the frequency of monitoring may increase access to PrEP.

Objective: To assess the non-inferiority of an internet-based HIV PrEP-service and reduced frequency of monitoring visits in comparison to standard-of-care at the Public Health Service.

Study design: Randomised, non-blinded, controlled, parallel group, non-inferiority trial.

Study population: MSM and TGP of 18 years of age or older who are eligible for HIV PrEP according to NPP guidelines based on self-reported sexual behavior indicating HIV risk.

Intervention: The study takes place in four GGD regions in the Netherlands: Amsterdam, Haaglanden, Rotterdam-Rijnmond and Gelderland-Zuid. Participants will be assigned to one of four arms: (1) routine care with quarterly monitoring at CSH; (2) routine care with biannual monitoring at CSH; (3) internet-based PrEP-care (i.e. video consultations and online-mediated testing for HIV, STIs and renal function) with quarterly monitoring; (4) internet-based PrEP-care with biannual monitoring. Each participant will be followed for 18 months.

Main study parameters/endpoints: The primary outcome is adherence to PrEP, determined by self-reported daily data on pill-intake and sexual behavior. Non-adherence is defined as a PrEP-less and condom-less anal sex act with a casual partner. Secondary outcomes include the incidence of HIV and Hepatitis C virus infections and bacterial STIs; creatinine clearance, glycosuria and proteinuria; retention in PrEP-care; psychosocial health; and acceptance and usability of the internet-based PrEP service.

Eligibility criteria: Inclusion Criteria:

* Aged 18 years or older;
* Meeting the eligibility criteria of the NPP i.e. being a MSM or transgender persons who in the 6 months prior to the PrEP-request/PrEP-consultation:

  * Had anal sexual intercourse without a condom with a male partner with an un-known HIV status, and/or;
  * Had anal sexual intercourse without a condom with a male partner with a known HIV-positive status and a detectable viral load, and/or;
  * Was diagnosed with a rectal STI, and/or;
  * Received a prescription for post-exposure prophylaxes (PEP);
* Living in the catchment area of one of the participating GGD regions;
* Having a smartphone, internet access and email address;
* Sufficient understanding of Dutch or English; and
* Signed informed consent.

Exclusion Criteria:

* HIV infection;
* Chronic or acute Hepatitis B virus infection;
* Diminishing renal function:
* eGFR less than 60 mL/min/1.73m2;
* Other renal problems, as diagnosed by a physician and advised against using TFV;
* Chronic use of medication that interacts with TFV/FTC e.g. NSAIDs.
* Other medical conditions that require special attention when using PrEP, such as osteoporosis or other bone diseases;
* Unlikely, in the opinion of the clinician, to comply with the study requirements or procedures;
* Participating in another study that affects the primary or secondary outcome measures of our study;
* Investigators or otherwise dependent persons.

Primary outcomes:
measure: Adherence to PrEP regimen
timeFrame: 18 months for each individual study participant
Secondary outcomes:
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Public Health Service of Amsterdam
city: Den Haag
country: Netherlands
facility: Public Health Service Haaglanden
city: Nijmegen
country: Netherlands
facility: Public Health Service Gelderland-Zuid
city: Rotterdam
country: Netherlands
facility: Public Health Service Rotterdam-Rijnmond
Study officials:
affiliation: Public Health Service of Amsterdam
name: Udi Davidovich, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Public Health Service of Amsterdam
name: Maarten Schim van der Loeff
role: PRINCIPAL_INVESTIGATOR
References: